ClinBrain Secures Nearly RMB 200 Million in Series C Funding Led by Legend Capital with Participation from Guohe Investment

Recently,ClinBrain, a leading enterprise in medical big data, has completed a Series C financing round of nearly RMB 200 million, led by Legend Capital and participated by Guohe Investment.Following this round of financing, ClinBrain will continue to deepen its presence in the field of medical big data, explore the deep integration of big data and AI in the healthcare industry, advance underlying technology R&D and scenario-based applications, and accelerate the digital and intelligent transformation of the industry.

ClinBrain, a high-tech enterprise specializing in medical big data middle platforms and data-driven intelligent application services, was included in the Ministry of Industry and Information Technology’s list of “Little Giant” enterprises under the Specialized, Refined, Differential, and Innovative (SRDI) initiative in 2022. Operating in the lucrative medical big data sector, valued at nearly RMB 100 billion, the company has demonstrated strong competitive strength and development potential, playing a pivotal leading role in driving innovative development within the medical big data industry.

Since its establishment in 2013, ClinBrain has recognized that healthcare, as a data-intensive and knowledge-intensive industry, relies heavily on data support for clinical services, operational management, and medical research. Last year, Oracle’s $28.3 billion acquisition of Cerner further corroborated the fact that “data holds high value.” The company has been dedicated to hospital data governance and intelligent applications. Given the multitude of vendors building hospital business systems, the intricate software landscape, and inconsistent data standards, data governance has proven exceptionally challenging. From the outset, ClinBrain chose the “difficult yet right” path.

Leveraging the team’s years of industry experience and technical expertise, the company has overcome numerous challenges, such as: collecting data from hospital business systems without relying on interfaces; effectively identifying complex data structures within diverse business systems; performing effective cleansing of business data from different vendors and versions; establishing robust and practical data quality rules to enhance hospital data quality; and structuring unstructured data, including medical records and pathology reports.

Automated identification of data structures across various versions from over 500 business vendors through an extensive rule base and knowledge base; high-quality data cleansing achieved via 3,900+ embedded data cleaning and quality rules; and structured processing of unstructured data enabled by tens of millions of accumulated medical concept-term relationships and robust natural language processing (NLP) capabilities.Leveraging these core capabilities, ClinBrain has achieved automated governance of massive datasets, laying a solid foundation for rapid deployment.

ClinBrain Builds for Hospitals Through Robust Data Governance Capabilities"Data Brain", covering the Clinical Data Repository (CDR), Operational Data Repository (ODR), and Research Data Repository (RDR); built upon the "Data Brain""Technical Brain", including a series of technical components such as data search, intelligent mining, and knowledge transformation, to support data-driven and intelligent applications; building on the foundation of the “Data Brain” and “Technology Brain,” the company closely aligns with the frontline clinical and management needs of hospitals to develop data-driven and intelligent applications, including a clinical big data search engine, specialized disease and cohort studies, hospital operational management, DRG & DIP, intelligent VTE early warning, intelligent decision-making for rare diseases, and early warning of nursing adverse events; it continuously meets various scenario-based intelligent demands, thereby comprehensively constructing“Medical Brain”。

ClinBrain has served over 100 large Grade A tertiary hospitals, including West China Hospital, Ruijin Hospital, Changhai Hospital, Hubei Provincial People's Hospital, Guizhou Provincial People's Hospital, Guangxi Zhuang Autonomous Region People's Hospital, and Shanghai Mental Health Center, through its comprehensive product portfolio, effectively helping these institutions enhance service quality and reduce costs.

(Figure: ClinBrain's Business Model)

Amid the COVID-19 pandemic, the healthcare digitalization industry has achieved counter-trend growth. The Central Committee of the Communist Party of China and the State Council have increased strategic deployment and investment in the healthcare sector, with policy documents such as the “Opinions on Promoting High-Quality Development of Public Hospitals” accelerating the rapid integration of next-generation information technologies into healthcare services.

Regarding this financing round,Liu Huanchun, Chairman of ClinBrainstated, “Against the current backdrop of a complex and volatile economy and the ongoing pandemic, the company’s recognition by Legend Capital and Guohe Investment underscores its market position, technological capabilities, and value potential. With this round of financing, the company will further strengthen its efforts in technological innovation and talent acquisition, propelling its development to a new level.”

Chen Rui, Co-Chief Investment Officer of Legend Capitalstated: “Medical big data plays a pivotal role in driving the digital and intelligent transformation of the pharmaceutical industry, aligning with the long-term trend of new healthcare infrastructure development. As a leading enterprise in China’s medical big data sector, ClinBrain boasts extensive theoretical knowledge and practical experience in the industry, offering end-to-end solutions ranging from data governance to application in healthcare scenarios. We are optimistic about the company’s continued expansion into more products and customer application scenarios, fostering new models of development in the medical big data landscape.”

Pu Wei, Managing Director of Guohe Investmentstated: “Guohe Investment is optimistic about the social and commercial value of healthcare big data. The ClinBrain team has been deeply engaged in the field of healthcare big data, gradually developing standardized products that provide end-to-end solutions—from data governance to clinical scenario applications—for numerous industry clients. This has secured its leading position in the sector and laid a solid foundation for future continuous upgrades and development. We are bullish on ClinBrain’s long-term growth.”

Legend Capital, established in April 2001, is a fund management company under Legend Holdings that specializes in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through its proactive value-added service system, Legend Capital drives innovative corporate growth, consistently delivering strong investment returns across multiple sectors while advancing China’s industrial progress and social development. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Prosperity with Integrity” and actively fulfills its social responsibilities.

Guohe Investment is a market-oriented investment institution jointly established by Shanghai International Group, the financial holding platform of the Shanghai Municipal Government, and private enterprises. Focusing on industrial intelligence, digital transformation, and technological innovation, Guohe Investment was named “Investment Firm of the Year” in 2020 and 2021, and “Best Exit Investment Firm of the Year” in 2021 by PEAS; ranked among the “Top 100 Private Equity Investment Firms in China” and “Top 50 State-Owned Capital Investment Firms in China” by Zero2IPO in 2020; recognized as the “Best Modern Service Industry Investment Firm” and “Fintech Investment Firm” in 2019, and listed among the “Top 50 Private Equity Funds of the Year” in 2020 by Yicai (First Financial); honored as an “Influential Growth-Stage Investment Firm” in the 2019 VC/PE Influence Investment Rankings by China Renaissance Holdings Limited; and consecutively included in the Category A list of insurance-funded private equity investment managers in 2020 and 2021.